Skip to Main Content

Paper Details

Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.
Cancer Discov
24
2022
-Producing TFH, Blood central memory TFH, CD38, CD38+ TFH, CD4+, CD8, CXCL13, E, E. coli, Escherichia coli, ICB, IgG, IgG4, IgG4+, IgG4+CD38+ TFH, MIBC, Muscle-Invasive Bladder Cancer, PD-1, PD-L1, TFH, bladder cancer, follicular helper CD4+ T cells, muscle-invasive bladder cancers, patients, pembrolizumab, tumor, tumors
Author NameAffiliation
Florent Ginhoux
Florent GinhouxShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine
Florent Ginhoux
Florent GinhouxUniversite Paris-Saclay
Michiel S van der HeijdenNetherlands Cancer Institute
Michiel S van der HeijdenNetherlands Cancer Institute
Miriam MeradThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai
Miriam MeradIcahn School of Medicine at Mount Sinai
Miriam MeradThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Miriam MeradIcahn School of Medicine at Mount Sinai
Miriam MeradInstitute for Thoracic Oncology, Icahn School of Medicine at Mount Sinai
Miriam MeradThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai
Miriam MeradIcahn School of Medicine at Mount Sinai
Miriam MeradThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Miriam MeradIcahn School of Medicine at Mount Sinai
Miriam MeradInstitute for Thoracic Oncology, Icahn School of Medicine at Mount Sinai
  • 1 - 16

Datasets

Release 1.2